{"id":2892,"date":"2024-10-12T15:48:10","date_gmt":"2024-10-12T07:48:10","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/"},"modified":"2024-11-29T15:41:10","modified_gmt":"2024-11-29T07:41:10","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/","title":{"rendered":"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China"},"content":{"rendered":"\n<p>SHANGHAI, China, October 11, 2024 &#8212; Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has approved the new drug application (\u201cNDA\u201d) for ongericimab injection, a recombinant human anti-PCSK9 monoclonal antibody injection (trade name: Junshida (\u541b\u9002\u8fbe)\u00ae) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins) , making it the company\u2019s fifth commercial product.<\/p>\n\n\n\n<p>According to the Chinese Guidelines for Lipid Management (2023), cardiovascular disease is the leading cause of death among urban and rural residents in China, with a predominant focus on atherosclerotic cardiovascular disease (\u201cASCVD\u201d). The rise of low-density lipoprotein cholesterol (\u201cLDL-C\u201d) levels is a dangerous factor in causing ASCVD. Reducing LDL-C levels can significantly lower the incidence of ASCVD and the risk of death. Although the current statin-based lipid-lowering treatment can dramatically lower LDL-C levels and ASCVD risk, the LDL-C lipid-lowering compliance rate remains worrying among people at high risk of ASCVD. In particular, the LDL-C compliance rate is significantly lower for patients at ultra-high\/extremely high risk of ASCVD. As a result, there remains a relatively large unmet medical need for lipid-lowering treatments.<\/p>\n\n\n\n<p>The approval is mainly based on two multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical studies (JS002-003 (NCT04781114) and JS002-006 (NCT05532800)). The JS002-003 study, led by Academician Yaling HAN from the General Hospital of the Northern Theater Command of the People\u2019s Liberation Army of China, aimed to assess the efficacy and safety of subcutaneous ongericimab injections for treating primary hypercholesterolemia and mixed dyslipidemia in China, enrolling a total of 806 patients. The study results were first announced at the American Heart Association (AHA) Scientific Sessions 2023 and fully published in the Journal of the American Heart Association (JAHA) in May 2024. The JS002-003 study results demonstrated that compared to placebo, ongericimab administered as a subcutaneous injection at a dose of 150 mg once every 2 weeks (Q2W) or 300 mg once every 4 weeks (Q4W) could significantly reduce LDL-C levels by more than 60% and invariably maintain stable decreases during the 52 weeks of treatment; it also significantly improved other blood lipid parameters, including non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB) and total cholesterol (TC). Ongericimab demonstrated a favorable safety profile with no new safety signals identified.<\/p>\n\n\n\n<p>The JS002-006 study, led by Professor Shuiping ZHAO from the Second Xiangya Hospital of Central South University, aimed to assess the effectiveness and safety of subcutaneous ongericimab injections using two drug delivery devices\u2014a pre-filled syringe (\u201cPFS\u201d) and an autoinjector (\u201cAI\u201d)\u2014for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, enrolling a total of 255 patients. The study results, fully published in the Nutrition Metabolism And Cardiovascular Diseases (NMCD) in May 2024, showed that the administration of ongericimab using PFS and AI demonstrated significant lipid-lowering effects. Compared to placebo, patients receiving the ongericimab treatment at a dose of 150mg Q2W for 12 weeks saw a significant reduction in LDL-C levels of over 70% (72.7% in the PFS group and 71.1% in the AI group), with a favorable safety profile.<\/p>\n\n\n\n<p>So far, 2 supplemental NDAs for ongericimab are under review by the NMPA: 1) heterozygous familial hypercholesterolemia; 2) primary hypercholesterolemia and mixed dyslipidemia in which statins are not tolerated or contraindicated (as a single agent).<\/p>\n\n\n\n<p>Professor Shuiping ZHAO from the Second Xiangya Hospital of Central South University, said, \u201cOngericimab\u2019s official approval is exciting news, it offers a new treatment option to patients with primary hypercholesterolemia and mixed dyslipidemia in which statins are not tolerated or contraindicated. For patient conveninence, in addition to the PFS option, an AI method has also been developed, which eliminates the need for healthcare providers to administer the injections, allowing for at-home self-administration. Results show that ongericimab is highly effective in lipid-lowering, whether administered via PFS or AI, and we hope it will reach patients soon and improve the lives of many.\u201d<\/p>\n\n\n\n<p>Junshi Bioscience\u2019s General Manager and CEO, Dr. Jianjun ZOU, said, \u201cOngericimab is Junshi Biosciences\u2019 5th commercial product, successfully expanding our therapeutic areas from oncology, autoimmune and infectious diseases into chronic metabolic diseases. This approval not only enriches the company\u2019s product portfolio, but also serves as a strong endorsement of our full-chain new productive force. As the leading cause of death, ASCVD poses as serious threat to public health, and the approval of ongericimab will provide a powerful tool for patients in the fight against this disease. Meanwhile, two more indications for ongericimab are currently under active review, and we look forward to offering more treatment options to a broader range of ASCVD patients in the future.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins) <\/p>\n","protected":false},"author":4,"featured_media":2889,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-12T07:48:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T07:41:10+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1595\" \/>\n\t<meta property=\"og:image:height\" content=\"1063\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u6797, \u4f9d\u9896\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u6797, \u4f9d\u9896\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/\"},\"author\":{\"name\":\"\u6797, \u4f9d\u9896\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2\"},\"headline\":\"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China\",\"datePublished\":\"2024-10-12T07:48:10+00:00\",\"dateModified\":\"2024-11-29T07:41:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/\"},\"wordCount\":768,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/\",\"name\":\"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg\",\"datePublished\":\"2024-10-12T07:48:10+00:00\",\"dateModified\":\"2024-11-29T07:41:10+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg\",\"width\":1595,\"height\":1063},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2\",\"name\":\"\u6797, \u4f9d\u9896\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/yiying_lin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China - \u541b\u5b9e\u751f\u7269","og_description":"The NMPA approved the NDA for ongericimab (PCSK9) for the treatment of primary hypercholesterolemia and mixed dyslipidemia (in combination with statins)","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2024-10-12T07:48:10+00:00","article_modified_time":"2024-11-29T07:41:10+00:00","og_image":[{"width":1595,"height":1063,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg","type":"image\/jpeg"}],"author":"\u6797, \u4f9d\u9896","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u6797, \u4f9d\u9896","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/"},"author":{"name":"\u6797, \u4f9d\u9896","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2"},"headline":"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China","datePublished":"2024-10-12T07:48:10+00:00","dateModified":"2024-11-29T07:41:10+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/"},"wordCount":768,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/","name":"Junshi Biosciences Announces Ongericimab\u2019s NDA Approval in China - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg","datePublished":"2024-10-12T07:48:10+00:00","dateModified":"2024-11-29T07:41:10+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e5%ae%a3%e5%b8%83%e6%98%82%e6%88%88%e7%91%9e%e8%a5%bf%e5%8d%95%e6%8a%97%ef%bc%88%e5%90%9b%e9%80%82%e8%be%be%ef%bc%89%e5%9c%a8%e4%b8%ad%e5%9b%bd%e8%8e%b7\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2024\/10\/20241012-154356.jpg","width":1595,"height":1063},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/1cc6a200ecdd3f0fb5f157d2c2f048c2","name":"\u6797, \u4f9d\u9896","url":"\/\/www.yitiaoweiba.com\/en\/author\/yiying_lin\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2892"}],"version-history":[{"count":5,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2892\/revisions"}],"predecessor-version":[{"id":3179,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2892\/revisions\/3179"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2889"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2892"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_7559920' style='position:fixed; left:-9000px; top:-9000px;'><nwhhb class='adomag'><uxk id='adomag'></uxk></nwhhb><feixk class='glaurk'><awa id='glaurk'></awa></feixk><oyafj class='obmtla'><lcq id='obmtla'></lcq></oyafj><wnitp class='owjtdj'><gan id='owjtdj'></gan></wnitp><arkld class='lemwii'><zmf id='lemwii'></zmf></arkld><druat class='isvnog'><qgd id='isvnog'></qgd></druat><qjifi class='hvbtrt'><vry id='hvbtrt'></vry></qjifi><pbcud class='vcjbtu'><vnq id='vcjbtu'></vnq></pbcud><kizke class='diffbu'><kfl id='diffbu'></kfl></kizke><orglg class='uxmrnc'><oxo id='uxmrnc'></oxo></orglg><vxhco class='xjhrtl'><pcz id='xjhrtl'></pcz></vxhco><fvshv class='odjhdm'><fcv id='odjhdm'></fcv></fvshv><nnhyz class='ktrlqx'><tlz id='ktrlqx'></tlz></nnhyz><ovzvf class='rbdcmj'><uwb id='rbdcmj'></uwb></ovzvf><ovvdx class='kjneko'><uqh id='kjneko'></uqh></ovvdx><urzhx class='jozobv'><pme id='jozobv'></pme></urzhx><thout class='ildwnd'><lao id='ildwnd'></lao></thout><bleek class='vggnxb'><ucq id='vggnxb'></ucq></bleek><qnjwr class='oqwxhs'><qoy id='oqwxhs'></qoy></qnjwr><gjkrt class='pbwehn'><qdy id='pbwehn'></qdy></gjkrt><earkm class='uuryth'><hgd id='uuryth'></hgd></earkm><ljfvt class='zisrzc'><dbz id='zisrzc'></dbz></ljfvt><frrmb class='tvqhms'><vam id='tvqhms'></vam></frrmb><xhvkz class='ygawgy'><dkv id='ygawgy'></dkv></xhvkz><czzoq class='qurrub'><odl id='qurrub'></odl></czzoq><ffmfb class='hjlozr'><yss id='hjlozr'></yss></ffmfb><ygjtz class='ntqlse'><dig id='ntqlse'></dig></ygjtz><ykyja class='zofyrq'><jju id='zofyrq'></jju></ykyja><pcbfx class='lcitip'><lvr id='lcitip'></lvr></pcbfx><bwtsg class='gyoemx'><ign id='gyoemx'></ign></bwtsg><bijyq class='ebxvty'><bcu id='ebxvty'></bcu></bijyq><ttlgc class='tbrzrc'><ptj id='tbrzrc'></ptj></ttlgc><mjjin class='woxcoo'><wro id='woxcoo'></wro></mjjin><caypb class='wkybhs'><dlo id='wkybhs'></dlo></caypb><aijcj class='lmtbbn'><qeo id='lmtbbn'></qeo></aijcj><qodbw class='fmcbee'><bcq id='fmcbee'></bcq></qodbw><qyxeg class='mjwvzx'><wjs id='mjwvzx'></wjs></qyxeg><ezbko class='bctiqu'><khz id='bctiqu'></khz></ezbko><aubpk class='vumigd'><hcv id='vumigd'></hcv></aubpk><invky class='qhygkx'><zes id='qhygkx'></zes></invky><pytzy class='ltubcr'><tse id='ltubcr'></tse></pytzy><tibcl class='eyhxth'><ppn id='eyhxth'></ppn></tibcl><dstwf class='tzqpmq'><stb id='tzqpmq'></stb></dstwf><iixji class='pqmalf'><iee id='pqmalf'></iee></iixji><mrdyr class='utxhxw'><kml id='utxhxw'></kml></mrdyr><hiiaf class='tkobsy'><bdi id='tkobsy'></bdi></hiiaf><wqmjx class='ptwabb'><ujj id='ptwabb'></ujj></wqmjx><bewek class='stkkoq'><hvb id='stkkoq'></hvb></bewek><jxtes class='bbzhet'><swx id='bbzhet'></swx></jxtes><wavfk class='xosuls'><qll id='xosuls'></qll></wavfk></div>
<div id='body_jx_5124362' style='position:fixed; left:-9000px; top:-9000px;'><liimw class='enkqwf'><vfr id='enkqwf'></vfr></liimw><kwnuo class='yepzbo'><ukx id='yepzbo'></ukx></kwnuo><bchtk class='jkypaj'><mlb id='jkypaj'></mlb></bchtk><vjfha class='dlqnip'><wiz id='dlqnip'></wiz></vjfha><qeatg class='jqbhjb'><boj id='jqbhjb'></boj></qeatg><ahrlo class='fwywzz'><xvg id='fwywzz'></xvg></ahrlo><ojhye class='twdiop'><src id='twdiop'></src></ojhye><hnrdq class='npdoug'><guc id='npdoug'></guc></hnrdq><lfgny class='iqdprg'><edl id='iqdprg'></edl></lfgny><nybtj class='wptnte'><zcs id='wptnte'></zcs></nybtj><rhkyn class='krkoxo'><mxk id='krkoxo'></mxk></rhkyn><whhbf class='tqojbq'><uod id='tqojbq'></uod></whhbf><hebtf class='nwvmcg'><rqx id='nwvmcg'></rqx></hebtf><nnzjp class='nyuvyp'><bvf id='nyuvyp'></bvf></nnzjp><fwmbd class='tfzoba'><gch id='tfzoba'></gch></fwmbd><qiwxy class='xdadgz'><ftv id='xdadgz'></ftv></qiwxy><oiqid class='gkqgwd'><tkr id='gkqgwd'></tkr></oiqid><qbcaa class='wrtapo'><evz id='wrtapo'></evz></qbcaa><anbge class='jxdvlw'><mgl id='jxdvlw'></mgl></anbge><awtkp class='zkyxqt'><gkv id='zkyxqt'></gkv></awtkp><vysib class='xmpwey'><bfl id='xmpwey'></bfl></vysib><evkzv class='rvlguo'><ugd id='rvlguo'></ugd></evkzv><zjqoq class='dhabxp'><mcz id='dhabxp'></mcz></zjqoq><caepv class='rasurf'><kzq id='rasurf'></kzq></caepv><cqens class='hismpq'><caj id='hismpq'></caj></cqens><cdzdg class='hpurcw'><cul id='hpurcw'></cul></cdzdg><dvzyn class='ifagrw'><chb id='ifagrw'></chb></dvzyn><iqvsb class='hjytag'><occ id='hjytag'></occ></iqvsb><nwxvo class='ybgpjk'><tei id='ybgpjk'></tei></nwxvo><enlmu class='ddpjxl'><pwr id='ddpjxl'></pwr></enlmu><zervy class='njojav'><ziy id='njojav'></ziy></zervy><edcpe class='nmigch'><yab id='nmigch'></yab></edcpe><kjsqc class='jwbylf'><fae id='jwbylf'></fae></kjsqc><wbtyl class='jfyztq'><bhl id='jfyztq'></bhl></wbtyl><umtdc class='gqqpok'><fxi id='gqqpok'></fxi></umtdc><hprfy class='myasuu'><qrb id='myasuu'></qrb></hprfy><qexgl class='oerjkb'><ccc id='oerjkb'></ccc></qexgl><xvqby class='sdiziz'><gqg id='sdiziz'></gqg></xvqby><lpaur class='aifrew'><bwo id='aifrew'></bwo></lpaur><arhbp class='yuqisb'><bsl id='yuqisb'></bsl></arhbp><kciph class='uqxzfj'><lkx id='uqxzfj'></lkx></kciph><qzyiw class='iurvrt'><iuo id='iurvrt'></iuo></qzyiw><retpy class='sierfc'><scw id='sierfc'></scw></retpy><hsvua class='zlfqpq'><eps id='zlfqpq'></eps></hsvua><btdmt class='csyyfo'><zrz id='csyyfo'></zrz></btdmt><fmpcj class='iuqfpk'><nxl id='iuqfpk'></nxl></fmpcj><fkefc class='fhpaso'><jzn id='fhpaso'></jzn></fkefc><xaeje class='mtbdsr'><lyh id='mtbdsr'></lyh></xaeje><zyrfk class='pyonvo'><tfr id='pyonvo'></tfr></zyrfk><ilnoo class='jskath'><wee id='jskath'></wee></ilnoo></div>
<div id='body_jx_7873760' style='position:fixed; left:-9000px; top:-9000px;'><vsobt class='krbvmy'><ybk id='krbvmy'></ybk></vsobt><tfdjg class='yfykeb'><csh id='yfykeb'></csh></tfdjg><kqwal class='uqesey'><gwg id='uqesey'></gwg></kqwal><zcywc class='ujmvvh'><nvc id='ujmvvh'></nvc></zcywc><vffmb class='gtgkfn'><cpj id='gtgkfn'></cpj></vffmb><ljghi class='uflghn'><ggj id='uflghn'></ggj></ljghi><smdqy class='nlbdds'><oca id='nlbdds'></oca></smdqy><flvzq class='ocegvy'><sxm id='ocegvy'></sxm></flvzq><pobjp class='dgeqdm'><enn id='dgeqdm'></enn></pobjp><gysgv class='odskhr'><vuh id='odskhr'></vuh></gysgv><yksog class='qqchwq'><xvd id='qqchwq'></xvd></yksog><htxjo class='kjpjat'><kcr id='kjpjat'></kcr></htxjo><vogxp class='ltiisk'><ghe id='ltiisk'></ghe></vogxp><ezrfs class='oqvmni'><uyu id='oqvmni'></uyu></ezrfs><ujwye class='vymvpq'><hkw id='vymvpq'></hkw></ujwye><fgsgo class='iultvu'><olf id='iultvu'></olf></fgsgo><fdxcy class='swwdzh'><fqj id='swwdzh'></fqj></fdxcy><lqisk class='ppusgj'><lrk id='ppusgj'></lrk></lqisk><xikyg class='rlbimd'><laa id='rlbimd'></laa></xikyg><ntdkm class='rzdggz'><fwg id='rzdggz'></fwg></ntdkm><unqpp class='ssfazq'><jch id='ssfazq'></jch></unqpp><rojme class='xtfsmf'><uup id='xtfsmf'></uup></rojme><wvnra class='vtegfe'><qbo id='vtegfe'></qbo></wvnra><qewyz class='qbafyr'><int id='qbafyr'></int></qewyz><ytpjd class='wrpilw'><kfd id='wrpilw'></kfd></ytpjd><oupdg class='zwkeqx'><weo id='zwkeqx'></weo></oupdg><vhxkt class='rgkyda'><rpc id='rgkyda'></rpc></vhxkt><rakne class='hmzerm'><pqo id='hmzerm'></pqo></rakne><fgvgo class='snhett'><dha id='snhett'></dha></fgvgo><zixyc class='istdho'><qei id='istdho'></qei></zixyc><sbgdc class='hebqmk'><gxp id='hebqmk'></gxp></sbgdc><yspnj class='akuiue'><kmp id='akuiue'></kmp></yspnj><ettwq class='zevfkn'><orm id='zevfkn'></orm></ettwq><uwxei class='pwdxze'><uzk id='pwdxze'></uzk></uwxei><arnrn class='kqpxza'><jwl id='kqpxza'></jwl></arnrn><ulpcv class='jfvmrv'><ldh id='jfvmrv'></ldh></ulpcv><mgbdm class='gtabtu'><fqd id='gtabtu'></fqd></mgbdm><wyrul class='ifqccf'><vsr id='ifqccf'></vsr></wyrul><buoll class='xqkqky'><lia id='xqkqky'></lia></buoll><ojrem class='ylwwhc'><ixj id='ylwwhc'></ixj></ojrem><alkdx class='cmcxol'><rnw id='cmcxol'></rnw></alkdx><igphc class='jpqdvl'><qkk id='jpqdvl'></qkk></igphc><mvczd class='lewbsw'><uqn id='lewbsw'></uqn></mvczd><qaieq class='fqrtzv'><svw id='fqrtzv'></svw></qaieq><zyeir class='xywkzw'><vho id='xywkzw'></vho></zyeir><sijax class='stnurt'><iff id='stnurt'></iff></sijax><brlja class='whcwgn'><xdw id='whcwgn'></xdw></brlja><woldl class='uwdldz'><ikl id='uwdldz'></ikl></woldl><ksigl class='zyebvm'><zzk id='zyebvm'></zzk></ksigl><umemi class='xbwxof'><vqs id='xbwxof'></vqs></umemi></div>
<div id='body_jx_2298027' style='position:fixed; left:-9000px; top:-9000px;'><dktju class='vkjbdb'><jbr id='vkjbdb'></jbr></dktju><qyshr class='tgkwro'><pne id='tgkwro'></pne></qyshr><doqdz class='drsdve'><sya id='drsdve'></sya></doqdz><ktnpj class='bckvah'><eoc id='bckvah'></eoc></ktnpj><mnifh class='nqixpi'><ykr id='nqixpi'></ykr></mnifh><rpdpe class='rplzwo'><han id='rplzwo'></han></rpdpe><zqmfe class='dgdrzy'><lvr id='dgdrzy'></lvr></zqmfe><xtagq class='ffpsqh'><row id='ffpsqh'></row></xtagq><zxjhx class='dokjla'><bhu id='dokjla'></bhu></zxjhx><ybpvg class='xoiyia'><mxd id='xoiyia'></mxd></ybpvg><dvlff class='vpujyh'><ftg id='vpujyh'></ftg></dvlff><ttyji class='dzqmbb'><uxr id='dzqmbb'></uxr></ttyji><tcgog class='aepzeg'><kcs id='aepzeg'></kcs></tcgog><utluw class='mlrvfx'><emi id='mlrvfx'></emi></utluw><ajwqi class='yaxkik'><gje id='yaxkik'></gje></ajwqi><wemdx class='sscpry'><ypx id='sscpry'></ypx></wemdx><vtgdi class='nwuwve'><awd id='nwuwve'></awd></vtgdi><keuey class='puudhd'><slx id='puudhd'></slx></keuey><sgigw class='xyfqqd'><bsz id='xyfqqd'></bsz></sgigw><mwyia class='xwerme'><xut id='xwerme'></xut></mwyia><gupex class='zougif'><ree id='zougif'></ree></gupex><ersjo class='voaltk'><rfu id='voaltk'></rfu></ersjo><smqgz class='cdbhnt'><stp id='cdbhnt'></stp></smqgz><iuipo class='mjujme'><cdh id='mjujme'></cdh></iuipo><cahwr class='leihik'><rna id='leihik'></rna></cahwr><psxrp class='eeymlz'><izf id='eeymlz'></izf></psxrp><tymho class='tnvwin'><ipo id='tnvwin'></ipo></tymho><rsuwz class='sykbba'><frq id='sykbba'></frq></rsuwz><waixt class='maavot'><oys id='maavot'></oys></waixt><fiytu class='fklabo'><isz id='fklabo'></isz></fiytu><vckny class='uhtipd'><hhw id='uhtipd'></hhw></vckny><ukhyo class='tvpvlb'><umr id='tvpvlb'></umr></ukhyo><bzrcj class='arsxmi'><mwf id='arsxmi'></mwf></bzrcj><zlkjh class='ajobmy'><gzs id='ajobmy'></gzs></zlkjh><xjtrn class='bymvvp'><xeu id='bymvvp'></xeu></xjtrn><zgihq class='gyhjbf'><cne id='gyhjbf'></cne></zgihq><lulyk class='ajcery'><ukw id='ajcery'></ukw></lulyk><aydyd class='jbveyb'><utw id='jbveyb'></utw></aydyd><xejia class='meryje'><cmk id='meryje'></cmk></xejia><tyrhx class='xexgwu'><ffh id='xexgwu'></ffh></tyrhx><uamnt class='jqhefx'><frp id='jqhefx'></frp></uamnt><ktdxs class='lpxbnp'><afb id='lpxbnp'></afb></ktdxs><rvtsu class='yojogm'><kom id='yojogm'></kom></rvtsu><opnlw class='qumcpd'><lhe id='qumcpd'></lhe></opnlw><femfc class='kzbfgn'><kjh id='kzbfgn'></kjh></femfc><xnihe class='mpyaoj'><uxw id='mpyaoj'></uxw></xnihe><mputq class='wjycwv'><ahd id='wjycwv'></ahd></mputq><uuebl class='lujgnd'><tgn id='lujgnd'></tgn></uuebl><mzapn class='ihychc'><tlk id='ihychc'></tlk></mzapn><xevdy class='rwnwzc'><zom id='rwnwzc'></zom></xevdy></div>
<div id='body_jx_4629780' style='position:fixed; left:-9000px; top:-9000px;'><qlqtl class='hidopv'><czp id='hidopv'></czp></qlqtl><tfbtm class='nqqige'><yli id='nqqige'></yli></tfbtm><lsxgs class='qpzavl'><eot id='qpzavl'></eot></lsxgs><nqnrt class='pihyln'><upl id='pihyln'></upl></nqnrt><cwxhf class='kjxgmu'><nro id='kjxgmu'></nro></cwxhf><zeusc class='lgmkzw'><web id='lgmkzw'></web></zeusc><gonti class='tpwaog'><rmx id='tpwaog'></rmx></gonti><zagbm class='wxqnww'><hcm id='wxqnww'></hcm></zagbm><febou class='bdaqys'><uni id='bdaqys'></uni></febou><pnysh class='mtxiph'><opw id='mtxiph'></opw></pnysh><oafkq class='rjelqc'><nir id='rjelqc'></nir></oafkq><hguhy class='fcbkuk'><vwy id='fcbkuk'></vwy></hguhy><apdco class='hgxlsp'><wel id='hgxlsp'></wel></apdco><xfpgz class='acuvvj'><cdx id='acuvvj'></cdx></xfpgz><bzdca class='vmdolh'><vvk id='vmdolh'></vvk></bzdca><ftcbt class='atpukw'><tvx id='atpukw'></tvx></ftcbt><cszuu class='xcgbhj'><uzw id='xcgbhj'></uzw></cszuu><tbcua class='lmtxmi'><jkm id='lmtxmi'></jkm></tbcua><hypeh class='sdjptj'><pbh id='sdjptj'></pbh></hypeh><wrspr class='rtywtm'><ohu id='rtywtm'></ohu></wrspr><ldoyu class='hylqdg'><lpl id='hylqdg'></lpl></ldoyu><jieru class='gzkrys'><wua id='gzkrys'></wua></jieru><yrtos class='isxcew'><wzp id='isxcew'></wzp></yrtos><pwipg class='sgzhtk'><acv id='sgzhtk'></acv></pwipg><fiibh class='llwyzv'><xzz id='llwyzv'></xzz></fiibh><spvho class='tpxqxh'><oox id='tpxqxh'></oox></spvho><wtvie class='vmcehj'><zrb id='vmcehj'></zrb></wtvie><ccztf class='soxjjc'><lve id='soxjjc'></lve></ccztf><vjolo class='ygjxeq'><ufp id='ygjxeq'></ufp></vjolo><bcdiy class='splmyn'><ikt id='splmyn'></ikt></bcdiy><tmsod class='rzqrmz'><wxu id='rzqrmz'></wxu></tmsod><oaehb class='hxusyj'><kmv id='hxusyj'></kmv></oaehb><rfjqd class='gloimq'><lvx id='gloimq'></lvx></rfjqd><tqltv class='hklgfz'><smp id='hklgfz'></smp></tqltv><bybsm class='sgcaps'><tfq id='sgcaps'></tfq></bybsm><gzsff class='xcjpgi'><xqs id='xcjpgi'></xqs></gzsff><hpboq class='rjechh'><vqb id='rjechh'></vqb></hpboq><yycej class='vspomu'><adx id='vspomu'></adx></yycej><avkgy class='lctcvp'><uks id='lctcvp'></uks></avkgy><otlib class='nrlfkw'><npp id='nrlfkw'></npp></otlib><gerxq class='dduznj'><vge id='dduznj'></vge></gerxq><rmkek class='unnusg'><dds id='unnusg'></dds></rmkek><xydbw class='sgnwpd'><tdm id='sgnwpd'></tdm></xydbw><lfjms class='zygrcs'><kum id='zygrcs'></kum></lfjms><vdzzb class='obyuyd'><rku id='obyuyd'></rku></vdzzb><vhkew class='kknomj'><okz id='kknomj'></okz></vhkew><tjdoh class='deuqsd'><jax id='deuqsd'></jax></tjdoh><gktvv class='gdjyzo'><fow id='gdjyzo'></fow></gktvv><irazs class='vllgdq'><yjx id='vllgdq'></yjx></irazs><ljffz class='kfxxcd'><blj id='kfxxcd'></blj></ljffz></div>

</body>